Key Highlights
- Shares are trading up 2.41% at $699.10, near the $711.85 52-week high.
- Third-quarter Revenue grew 9% to $12.14 billion with adjusted EPS of $6.68.
- Full-year adjusted EPS guidance was raised to a range of $25.13 to $25.43.
Thermo Fisher Scientific (NYSE:TMO) shares are trading up 2.41% at $699.10 today as life-science tools peers report strong results, with Revvity (NYSE:RVTY) jumping on a third-quarter beat and a raised 2026 outlook. The move follows a 2.06% decline in the prior session, and the stock is trading close to its 52-week high of $711.85 set on October 29, against a 52-week low of $435.27.
Thermo Fisher is a Waltham, Massachusetts-based science and diagnostics company that generated about $44.56 billion in revenue in 2025. It operates through Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, selling under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon and PPD.
Peer Strength Revives Demand Optimism in Life-Science Tools
Revvity's results pointed to improving pharma and biotech demand and broadening AI-related orders, which gave the whole group a lift. Thermo Fisher's own October report had already beaten expectations, with adjusted EPS of $6.68 against an estimate of $6.40 and revenue of $12.14 billion against $12 billion expected.
Analyst support remains firm, with Citi at an $800 target and TD Cowen at $810, while Barclays and Guggenheim also reiterated their support. Insider selling of about $45.9 million over 90 days and DZ Bank's more cautious stance are the counterweights. The healthcare sector is benefiting from a rotation out of technology, though midterm elections and AI-trade Volatility keep the broader backdrop uncertain.
Third-Quarter Detail Shows Pharma Services and Margin Expansion
Third-quarter revenue grew 9% to $12.14 billion with 6% organic growth, adjusted Operating Income rose 15% to $2.97 billion and adjusted Operating Margin expanded 120 basis points to 24.5%. Results beat prior guidance by more than $200 million in revenue and about $0.26 in EPS, including roughly $0.15 from one-time Tariff refunds.
Pharma and biotech grew high single digits, led by pharma services, the research and safety market channel and clinical research. By segment, organic growth was 1% in Life Sciences Solutions, 6% in Analytical Instruments, flat in Specialty Diagnostics and 10% in Laboratory Products and Biopharma Services. Bioproduction was the strongest Business in Life Sciences Solutions, and high-tech reagents are expected to improve over the next couple of quarters as biotech recovers.
Raised 2026 Guidance and a Path Back to 7% Organic Growth
Full-year revenue guidance was raised to $47.7 billion to $48.2 billion, with organic growth of 4%, and adjusted EPS guidance moved up to $25.13 to $25.43, about 10% to 11% growth. Free Cash Flow is expected at $7 billion to $7.5 billion.
Fourth-quarter organic growth is guided to 4%, below the third quarter's 6%, because some pharma services activity was pulled into Q3. Management expects second-half organic growth of about 5% and sees a path back to roughly 7% organic growth by late 2027 or early 2028. Capital deployment assumes $4 billion of Buybacks and about $700 million of dividends.
Capital Returns and Acquisitions Support the Longer-Term Case
Management cited AI deployment, the Clario and filtration acquisitions and a recovering biotech market as drivers of the multi-year plan. With peers confirming improving demand, attention stays on whether Thermo Fisher can hold the gains near its 52-week high.






Please wait processing your request...